BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Clinical Trials

Keymed Biosciences Advances CDH17-Targeted ADC CM518D1 Into Phase I/II Trials for Solid Tumors in China

Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced CM518D1, a CDH17-targeted antibody-drug conjugate (ADC) develop...

April 28, 2025 | News

Akeso’s Ivonescimab Outperforms Pembrolizumab in Phase III, Wins NMPA Approval for First-Line PD-L1-Positive NSCLC

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that its globally first-in-class PD-1/VEGF bispecific antibody, ivonescimab, has re...

April 28, 2025 | News

Innovent Biologics Secures NMPA Approval for Limertinib as First-Line Therapy for EGFR-Mutated NSCLC in China

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...

April 28, 2025 | News

Sun Pharma and Moebius Medical Showcase Durable Pain Relief and Cartilage Protection with MM-II for Knee Osteoarthritis

Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA models featured in two peer-reviewed articles - - New d...

April 25, 2025 | News

Suvoda and Greenphire Merge to Create Unified Platform for Streamlining Clinical Trials

Suvoda, a global clinical trial technology company specializing in randomization and trial supply management, consent, and patient outcomes data collection...

April 25, 2025 | News

Doer Bio Begins Phase 2 Trial of Tri-Agonist DR10624 for MASLD and MASH Treatment

Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and...

April 24, 2025 | News

Onward Therapeutics Receives EMA Green Light for Phase 1 Trial of Allogeneic NK Cell Therapy in Relapsed DLBCL

Onward Therapeutics SA, a biotechnology company dedicated to advancing innovative cancer immunotherapies, announced that its subsidiary, Emercell SAS, has ...

April 23, 2025 | News

Sichuan Kelun-Biotech Secures FDA IND Clearance for First-in-Class ADC SKB518

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company has been granted the clearance of investigational new dru...

April 22, 2025 | News

Clarity Begins Phase II Dosing in SECuRE Trial for Prostate Cancer with Enhanced 67Cu-SAR-bisPSMA Formulation

The first of the planned 24 participants in the Cohort Expansion Phase (Phase II) of the SECuRE trial has been treated with their first dose of 8 GB...

April 16, 2025 | News

XellSmart Receives IND Approval from FDA for iPSC-Derived Cell Therapy in Parkinson’s Disease

In January 2025 (U.S. time), the U.S. Food and Drug Administration (FDA) officially approved the Investigational New Drug (IND) application submi...

April 16, 2025 | News

Telix Reports Positive Preliminary Results from IPAX-Linz Study of TLX101 in Recurrent High-Grade Glioma

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101&nb...

April 16, 2025 | News

Bristol Myers Squibb’s Opdivo Plus Yervoy Wins FDA Nod as First-Line Treatment for Advanced Liver Cancer

Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) approved Opdivo® (nivolumab) plus Yervoy® ...

April 14, 2025 | News

GPC-100, a CXCR4 Inhibitor, Moves Toward AML Trials Following Promising Preclinical and Phase 1 Data; Phase 2 in Multiple Myeloma Ongoing

Exicure, Inc. shared updates on its lead asset, GPC-100 (burixafor), a small molecule CXCR4 inhibitor. Exicure, Inc. (“Exicure”) is planning f...

April 14, 2025 | News

RemeGen’s Telitacicept Shows Best-in-Class Efficacy in Phase 3 Trial for Generalized Myasthenia Gravis

On April 8, 2025 (UTC-7), impressive results of the Phase 3 clinical trial (NCT05737160) evaluating the efficacy and safety of Telitacicept...

April 09, 2025 | News

Stay Connected